Veterinary Medicines

EURICAN DAPPI-L, κόνις και διαλύτης για ενέσιμο εναιώρημα για σκύλους

Authorised
  • Canine distemper virus, strain BA5, Live
  • Canine adenovirus 2, strain DK13, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Canine parainfluenza virus 2, Inactivated
Download as PDF

Ravimi identifitseerimine

Ravimi nimetus:
EURICAN DAPPI-L, κόνις και διαλύτης για ενέσιμο εναιώρημα για σκύλους
Toimeaine:
Loomaliigid:
  • koer
Manustamisviis:
  • Subkutaanne

Ravimiandmed

Toimeaine / Tugevus:
  • Turustatakse ainult English
    10000.00
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Turustatakse ainult English
    316.22
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Turustatakse ainult English
    79.43
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Turustatakse ainult English
    50.12
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Turustatakse ainult English
Ravimvorm:
  • Süstesuspensiooni pulber ja lahusti
Withdrawal period by route of administration:
  • Subcutaneous use
    • koer
Veterinaarravimite anatoomilis-terapeutilise keemilise klassifikatsiooni (ATCvet) kohane kood:
  • QI07AI02
Õiguslik tarnestaatus:
  • Retseptiravim - veterinaarravim
Müügiloa staatus:
  • Valid
Authorised in:
  • Kreeka
Pakendi kirjeldus:

Lisateave

Entitlement type:
Ravimi müügiloa õiguslik alus:
Müügiloa hoidja:
  • Boehringer Ingelheim Animal Health France
Marketing authorisation date:
Partii vabastamise tootmiskohad:
  • Boehringer Ingelheim Animal Health France
Vastutav asutus:
  • National Organization For Medicines
Authorisation number:
  • 38630/27-04-2017/K-0225001
Müügiloa staatuse muutmise kuupäev:
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."